Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses
- 3 September 2002
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 53 (2) , 95-100
- https://doi.org/10.1002/pros.10138
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- TREATMENT OF HUMAN RENAL CELL CARCINOMA BY A CONDITIONALLY REPLICATING HERPES VECTOR G207Journal of Urology, 2001
- SUICIDE GENE THERAPY TOXICITY AFTER MULTIPLE AND REPEAT INJECTIONS IN PATIENTS WITH LOCALIZED PROSTATE CANCERJournal of Urology, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivityInternational Journal of Cancer, 1999
- In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical TrialHuman Gene Therapy, 1999
- Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1Human Gene Therapy, 1998
- In VivoGene Therapy for Prostate Cancer: Preclinical Evaluation of Two Different Enzyme-Directed Prodrug Therapy Systems Delivered by Identical Adenovirus VectorsHuman Gene Therapy, 1998
- Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancerInternational Journal of Cancer, 1997
- Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomasNature Medicine, 1995
- In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020: Construction and Evaluation in RodentsThe Journal of Infectious Diseases, 1988